德国Diarect AG
在过去的20年里，DIARECT AG公司的专家致力于自身免疫分析的大量创新研究与开发：
1、基于重组甲状腺过氧化物酶（TPO）的最早的甲状腺过氧化物酶抗体的测试系统；
2、使用了几种重组蛋白的最早的抗核抗体(ANA) /多肽抗体（ENA ）的分布和筛选分析；
3、最初的重组蛋白有增殖细胞核抗原（PCNA）, 苏胺酰-tRNA合成酶（PL-7）, 丙胺酰-tRNA合成酶(PL-12) , 全长的 Mi-2蛋白, Ku (p70/p80) 等.

我们的承诺是进一步扩大产品系列，在未来的几年来我们将继续致力于开发新的自身抗原。

在免疫分析产品方面多年的经验告诉我们，产品的性能取决于高品质的原料结合精益求精的研发。同等重要的还有关键原料质量的可重复性，从而使产品后继生产过程中的偏差降到最低。我们的专长是大批量生产以及保持各批次产品之间的一致性。

DIARECT AG的公司目标是通过提供优质产品来改善分析的质量水平从而增强分析性能。这个理念促使我们援助世界各地的病人和临床免疫学家，与研究人员的科学合作，以及我们自己进行的学术参与，都促使着我们在这个方向上努力。

 Over the last two decades our experts have been involved in a number of innovative autoimmune assay developments:

First thyroid peroxidase antibody test system, based on recombinant TPO
First ANA/ENA profile and screening assay, utilizing several recombinant proteins
Introduction recombinant PCNA, PL-7, PL-12, full length Mi-2ß, Ku (p70/p80) etc.
Since we are committed to further expand our product panel, we will strive to continue the development of new autoantigens in the years to come.

Manufacturing Experience
Years of experience in immunoassay production have taught us that test performance is the result of sophisticated assay development in combination with high-quality components. Equally important is the reproducible quality of these key components in order to minimize deviation in the subsequent manufacturing process. Large lot sizes as well as lot-to-lot consistency is our expertise.

Committed to Clinical Science
We at DIARECT AG aim to enhance assay performance by providing superior components for an improved assay quality level. This concept drives us to support patients and clinical immunologists worldwide. Scientific collaborations with researchers as well as our own ongoing academic involvement facilitate our efforts in this direction.